ArticleFrontiers in pediatrics2026
Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Progressive IgA nephropathy (IgAN) in childhood presents challenges for treatment. Telitacicept has shown significant benefits in adult IgAN patients, warranting investigation into its potential efficacy in the pediatric population. This study was designed to evaluate the changes in clinical parameters before and after telitacicept treatment in children with IgA nephropathy (IgAN). Methods: A single-center, self-controlled before-and-after study was conducted. Children received subcutaneous injections of telitacicept once weekly, in addition to ongoing background therapy (including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, glucocorticoids, and/or other immunosuppressants). The primary clinical parameter was the change in 24-hour urinary protein (24-h UP) from baseline. Secondary clinical parameters included changes in serum albumin (ALB), immunoglobulins, CD19+ B-cell count, estimated glomerular filtration rate (eGFR), and immunosuppressant dosage. Adverse events were recorded. Results: Eleven children were included. The 24-h UP level began a non-significant decline at week 4 ( Conclusion: In children with IgAN, telitacicept was associated with reduced proteinuria, facilitated immunosuppressant tapering, and demonstrated a favorable safety profile, while preserving renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.